Literature DB >> 19508595

Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note.

Fausto Bogazzi, Luca Tomisti, Claudia Ceccarelli, Enio Martino.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508595     DOI: 10.1111/j.1365-2265.2009.03600.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  6 in total

Review 1.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

2.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

3.  [Clinical practice guidelines for acute and chronic thyroiditis (excluding autoimmune thyroiditis)].

Authors:  E A Troshina; E A Panfilova; M S Mikhina; I V Kim; E S Senyushkina; A A Glibka; B M Shifman; A A Larina; M S Sheremeta; M V Degtyarev; P O Rumyanstsev; N S Kuznetzov; G A Melnichenko; I I Dedov
Journal:  Probl Endokrinol (Mosk)       Date:  2021-04-12

4.  Amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge.

Authors:  Umang Barvalia; Barkha Amlani; Ram Pathak
Journal:  Case Rep Med       Date:  2014-11-12

5.  Recombinant TSH and Lithium Overcomes Amiodarone-Induced Low Radioiodine Uptake in a Thyrotoxic Female.

Authors:  Nestor Eric R Laplano; Leilani B Mercado-Asis
Journal:  Int J Endocrinol Metab       Date:  2012-09-30

6.  Dysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases.

Authors:  Agata Czarnywojtek; Maria Teresa Płazińska; Małgorzata Zgorzalewicz-Stachowiak; Kosma Woliński; Adam Stangierski; Izabela Miechowicz; Joanna Waligórska-Stachura; Paweł Gut; Leszek Królicki; Maja Zioncheck; Marek Ruchała
Journal:  Ther Clin Risk Manag       Date:  2016-04-04       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.